The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Advanced prostate cancer, including metastatic and castration-resistant forms, lacks effective treatments.
• The CAMK2N1 gene, an inhibitor of calcium/calmodulin-dependent protein kinase II (CaMKII), influences tumorigenesis, but its role in prostate cancer is unclear.

Purpose of the Study:

• To investigate the role of CAMK2N1 in prostate cancer development and progression.
• To evaluate CAMK2N1 as a potential biomarker and therapeutic target for prostate cancer.

Main Methods:

• Examined CAMK2N1 protein and mRNA levels in human prostate cancer tissues versus normal tissues.
• Assessed the effects of CAMK2N1 re-expression and knockdown on prostate cancer cell proliferation, cell cycle, apoptosis, and associated signaling pathways (IGF-1, ErbB2, VEGF, PI3K/AKT, MEK/ERK).

Main Results:

• CAMK2N1 expression was significantly decreased in prostate cancers compared to normal tissues.
• Re-expression of CAMK2N1 suppressed proliferation, induced G0/G1 cell cycle arrest, and promoted apoptosis, while down-regulating key oncogenic signaling pathways.
• CAMK2N1 knockdown produced opposite effects, enhancing tumor cell phenotypes.
• Reduced CAMK2N1 expression correlated with prostate cancer progression and predicted poor clinical outcomes.

Conclusions:

• CAMK2N1 functions as a tumor suppressor in prostate cancer.
• Decreased CAMK2N1 expression is linked to disease progression and serves as a potential prognostic biomarker.
• CAMK2N1 represents a promising therapeutic target for prostate cancer treatment.